Nasdaq:INGN
Inogen Inc
Inogen Inc develops and markets portable oxygen concentrators that empower patients with chronic respiratory diseases to live more active lives.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in Inogen due to its dominant market position in the portable oxygen concentrator sector with a highly defensible product portfolio backed by strong patents. The narrowing net loss trend from 2022 to 2025 suggests improving operational efficiency, and the substantial cash balance of $103.7M provides a runway to fund growth initiatives without immediate dilution.
Bear Case
The stock faces substantial risk as the company posted a net profit deficit of $-22.7M in 2025 with no positive earnings history, indicating that current revenue levels are insufficient to cover operating expenses. With total liabilities reaching $106.4M and a retained earnings deficit of $-175.6M, the company relies heavily on capital raises or cash reserves to sustain operations while navigating a highly competitive landscape.
About Inogen Inc
Inogen Inc is a leading provider of portable oxygen concentrators and related respiratory therapy products designed to help patients with chronic respiratory conditions maintain an active lifestyle. The company primarily serves the United States market through its direct-to-consumer and healthcare professional channels, offering innovative medical devices that enable mobility and independence for individuals suffering from diseases like COPD.
Analysis
Management Discussion
Despite a recovery in 2024 and 2025 where net losses narrowed significantly from over $100 million in 2023 down to $22.7 million in 2025, the company continues to operate with negative cash flow from operations of $11.2 million. Management has invested heavily in marketing expenses totaling $97.7 million, which alongside general and administrative costs of $67.4M, contributes to an operating profit deficit of $30.2 million as they scale their direct sales infrastructure.
Industry Overview
The home medical equipment industry is experiencing steady demand driven by an aging population and increasing prevalence of chronic respiratory diseases such as COPD and pulmonary fibrosis. However, market growth faces headwinds from regulatory scrutiny regarding the high cost of oxygen therapy devices and potential policy shifts affecting Medicare coverage for durable medical equipment.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $377.2M | $315.7M | $335.7M | $348.7M |
| Cost of Revenue | $223.7M | $189.0M | $181.0M | $194.4M |
| Gross Profit | $153.5M | $126.7M | $154.7M | $154.3M |
| Operating Expenses | $238.8M | $236.1M | $197.3M | $184.5M |
| Operating Income | $-85.2M | $-109.4M | $-42.5M | $-30.2M |
| R&D | $21.9M | $20.8M | $21.6M | $19.4M |
| G&A | $43.9M | $75.3M | $72.6M | $67.4M |
| Marketing | $120.8M | $107.1M | $103.1M | $97.7M |
| Stock-Based Comp | $12.3M | $7.4M | $7.4M | $8.0M |
| D&A | $23.5M | $18.2M | $21.0M | $20.7M |
| Amortization | $8.5M | $1.2M | $4.3M | $4.9M |
| Other OpEx | $52.2M | $32.9M | $0 | $0 |
| Non-Operating Income | $2.0M | $7.0M | $6.0M | $6.8M |
| Interest Income | $2.8M | $6.6M | $5.2M | $4.4M |
| Pre-Tax Income | $-83.3M | $-102.3M | $-36.5M | $-23.4M |
| Income Tax | $504.0K | $105.0K | $-588.0K | $-632.0K |
| Continuing Ops | $-83.8M | $-102.4M | $-35.9M | $-22.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-83.8M | $-102.4M | $-35.9M | $-22.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-83.8M | $-102.4M | $-35.9M | $-22.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $304.6M | $207.1M | $185.5M | $198.3M |
| Cash & Equivalents | $187.0M | $125.5M | $113.8M | $103.7M |
| Accounts Receivable | $62.7M | $42.2M | $29.6M | $38.9M |
| Inventory | $34.1M | $21.8M | $24.8M | $26.0M |
| Prepaid Expenses | $19.2M | $13.8M | $13.1M | $12.6M |
| Other Current Assets | $1.6M | $3.6M | $4.2M | $17.1M |
| Long-Term Assets | $100.4M | $119.1M | $110.7M | $100.3M |
| PP&E (Net) | $43.3M | $50.3M | $44.4M | $36.4M |
| Goodwill | $32.9M | $10.1M | $9.5M | $10.7M |
| Operating Leases | $21.7M | $20.3M | $18.3M | $16.5M |
| Other LT Assets | $2.6M | $38.4M | $38.6M | $36.8M |
| Total Assets | $405.0M | $326.2M | $296.2M | $298.6M |
| Current Liabilities | $65.3M | $72.5M | $76.7M | $63.5M |
| Accounts Payable | $18.2M | $13.5M | $16.6M | $20.3M |
| Current Leases | $3.5M | $3.7M | $2.8M | $3.2M |
| Taxes Payable | — | $27.0K | $142.0K | $183.0K |
| Other Current Liab | $43.6M | $55.4M | $57.1M | $39.9M |
| Long-Term Liabilities | $42.3M | $48.9M | $45.6M | $42.9M |
| LT Operating Leases | $19.8M | $18.3M | $16.6M | $14.3M |
| Other LT Liab | $12.1M | $22.4M | $23.3M | $24.9M |
| Total Liabilities | $107.6M | $121.4M | $122.3M | $106.4M |
| Shareholders' Equity | $297.4M | $204.8M | $173.9M | $192.2M |
| Retained Earnings | $-14.5M | $-116.9M | $-152.8M | $-175.6M |
| AOCI | $-243.0K | $1.2M | $-1.5M | $4.2M |
| Total L&E | $405.0M | $326.2M | $296.2M | $298.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-83.8M | $-102.4M | $-35.9M | $-22.7M |
| Non-Cash Adjustments | $22.0K | $138.9M | $41.4M | $4.5M |
| Working Capital Changes | $46.2M | $-39.7M | $434.0K | $7.1M |
| Cash from Operations | $-37.5M | $-3.2M | $5.9M | $-11.2M |
| Capital Expenditures | $3.3M | $5.2M | $3.4M | $2.5M |
| Cash from Investing | $-10.9M | $-59.3M | $-14.0M | $-26.2M |
| Cash from Financing | $380.0K | $960.0K | $265.0K | $24.2M |
| FX Effect | $-481.0K | $67.0K | $-281.0K | $846.0K |
| Net Change in Cash | $-48.5M | $-61.5M | $-8.1M | $-12.4M |
| Beginning Cash | $235.5M | $187.0M | $125.5M | $117.4M |
| Ending Cash | $187.0M | $125.5M | $117.4M | $105.0M |
Frequently Asked Questions
How does Inogen Inc make money?
The company's revenue streams are driven by the sale of its proprietary portable oxygen concentrators, such as the Inogen One and Go models, sold directly to consumers via a robust distribution network. Additionally, significant revenue is generated through sales to healthcare professionals and institutions for use in clinical settings and long-term care facilities.
What are the main risks for INGN?
The company faces significant headwinds from potential changes in Medicare reimbursement rates or other payer policies that could impact the affordability and volume of oxygen concentrator purchases. Rising material and manufacturing costs combined with a narrowing gross profit margin create pressure on profitability, especially given the current operating loss. The direct-to-consumer model is capital intensive, requiring continuous investment in marketing to maintain customer acquisition amidst a slowing revenue growth trend.
What is INGN's competitive advantage?
Inogen possesses strong intellectual property protection around its proprietary technology that enables compact, lightweight oxygen generation units with extended battery life. The company benefits from a highly engaged direct-to-consumer sales model that builds strong brand loyalty among patients seeking to remain mobile while managing chronic conditions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.